Davide Chiasserini
Overview
Explore the profile of Davide Chiasserini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wojdala A, Bellomo G, Gaetani L, Teunissen C, Parnetti L, Chiasserini D
Nat Commun
. 2025 Jan;
16(1):214.
PMID: 39747866
Different forms of phosphorylated tau (p-tau) have shown strong potential as Alzheimer's disease (AD) biomarkers in both cerebrospinal fluid (CSF) and plasma. We hypothesized that p-tau proteoforms simultaneously phosphorylated at...
2.
Pampalone G, Chiasserini D, Pierige F, Camaioni E, Orvietani P, Bregalda A, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063173
The gyrate atrophy of the choroid and retina (GACR) is a rare genetic disease for which no definitive cure is available. GACR is due to the deficit of ornithine aminotransferase...
3.
Barba L, Bellomo G, Oeckl P, Chiasserini D, Gaetani L, Torrigiani E, et al.
J Neurol Sci
. 2024 Jun;
462:123059.
PMID: 38850771
Background: VGF and neuroserpin are neurosecretory proteins involved in the pathophysiology of neurodegenerative diseases. We aimed to evaluate their cerebrospinal fluid (CSF) concentrations in patients with Alzheimer's disease (AD) and...
4.
Di-Iacovo N, Ferracchiato S, Pieroni S, Scopetti D, Castelli M, Piobbico D, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731819
mutations are prevalent in various cancers, yet the complexity of apoptotic pathway deregulation suggests the involvement of additional factors. is known to extend the half-life of p53 under normal and...
5.
Njoku K, Pierce A, Chiasserini D, Geary B, Campbell A, Kelsall J, et al.
EBioMedicine
. 2024 Mar;
102:105064.
PMID: 38513301
Background: The anatomical continuity between the uterine cavity and the lower genital tract allows for the exploitation of uterine-derived biomaterial in cervico-vaginal fluid for endometrial cancer detection based on non-invasive...
6.
Bellomo G, Bayoumy S, Megaro A, Toja A, Nardi G, Gaetani L, et al.
Alzheimers Dement
. 2024 Feb;
20(4):2453-2468.
PMID: 38323780
Introduction: For routine clinical implementation of Alzheimer's disease (AD) plasma biomarkers, fully automated random-access platforms are crucial to ensure reproducible measurements. We aimed to perform an analytical validation and to...
7.
Bellomo G, Toja A, Paoletti F, Ma Y, Farris C, Gaetani L, et al.
Alzheimers Dement
. 2024 Feb;
20(4):2444-2452.
PMID: 38323747
Introduction: Lewy body disease, a frequently observed co-pathology in Alzheimer's disease (AD), can be identified antemortem in cerebrospinal fluid (CSF) by α-synuclein seed amplification assay (αS-SAA). The prevalence and clinical...
8.
Patera F, Gatticchi L, Cellini B, Chiasserini D, Reboldi G
Biomolecules
. 2024 Jan;
14(1).
PMID: 38275766
Kidney fibrosis, diffused into the interstitium, vessels, and glomerulus, is the main pathologic feature associated with loss of renal function and chronic kidney disease (CKD). Fibrosis may be triggered in...
9.
Wojdala A, Bellomo G, Gaetani L, Toja A, Chipi E, Shan D, et al.
Neurobiol Dis
. 2023 Nov;
189:106356.
PMID: 37977432
CSF-to-plasma transition will open new avenues for molecular phenotyping of Alzheimer's disease (AD). Here we evaluated a panel of AD biomarkers in matched CSF and plasma samples across the AD...
10.
Gaetani L, Chiasserini D, Paoletti F, Bellomo G, Parnetti L
Expert Rev Mol Diagn
. 2023 Oct;
23(12):1195-1207.
PMID: 37902844
Introduction: Cerebrospinal fluid (CSF) biomarkers represent a well-established tool for diagnosing Alzheimer's disease (AD), independently from the clinical stage, by reflecting the presence of brain amyloidosis (A+) and tauopathy (T+)....